Skip to main content

LCD L39071: Platelet Rich Plasma

LCD L39071, Platelet Rich Plasma, is the Local Coverage Determination that First Coast Service Options, Inc. applies to claims from 1 state plus 2 territories (FL, PR, VI), effective 2021-12-12. The policy text runs 52 words. 3 other contractor versions share this title, so the criteria depend on where the service is furnished. Counting every linked billing and coding article, this one lists 0 covered ICD-10-CM codes: the same total as L38745 (Palmetto GBA, 0 codes, revised 2025-03-13) and the same total as L38937 (Wellpoint Federal, 0 codes, revised 2026-04-01).

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
First Coast Service Options, Inc.
States and territories
3
FL PR VI
Revision effective
2021-12-12
Original effective
2021-12-12
Policy text
52 words
Covered ICD-10 codes (articles)
0

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L39071
ContractContractorTypeStates
09101First Coast Service Options, Inc.A and B MACFL
09201First Coast Service Options, Inc.A and B MACPR VI
09102First Coast Service Options, Inc.A and B MACFL
09202First Coast Service Options, Inc.A and B MACPR
09302First Coast Service Options, Inc.A and B MACVI

Billing and coding article A58810: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A58810 (Billing and Coding: Platelet Rich Plasma) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A58810: Billing and Coding: Platelet Rich Plasma (Billing and Coding, effective 2023-07-01)

Covered ICD-10-CM codes
0
0 groups
Non-covered ICD-10-CM codes
0
Procedure codes listed
6
Full article
cms.gov record

Procedure codes: 0232T, 0481T, G0460 (Autologous platelet rich plasma or other blood-derived product for non-diabetic chronic wounds/ulcers, including as applicable phlebotomy, centrifugation or mixing, and all other preparatory procedures, administration and dressings, per treatment), M0076 (Prolotherapy), P9020 (Platelet rich plasma, each unit), S9055 (Procuren or other growth factor preparation to promote wound healing).

Coverage indications, limitations and medical necessity

Compliance with the provisions in this LCD may be monitored and addressed through post payment data analysis and subsequent medical review audits.

Platelet rich plasma injections and/or applications are considered not medically reasonable and necessary for any use outside of the National Coverage Determination (NCD) 270.3 Blood-Derived Products for Chronic Non-Healing Wounds.

Summary of evidence (opening)

Introduction

Platelet-rich plasma (PRP) is defined as a platelet-rich concentrate with platelet levels greater than the baseline platelet count in whole blood. This autologous derived substance, also referred to as autologous platelet-derived growth factors, platelet gel, platelet-rich concentrate, autogenous platelet gel, plasma rich in growth factors, or platelet releasate, has been proposed for the treatment of multiple conditions to enhance healing. Theoretically, these growth factors function as a mitogen for fibroblasts, smooth muscle cells, osteoblasts, and vascular endothelial growth factors. 2,3 While PRP may work by activating the innate immune response and stimulating tissue anabolism, its precise action mechanism is still unclear. 3 The role that white blood cells may play is particularly unclear, as the immune cells may act as antimicrobial and/or proinflammatory agents. Furthermore, PRP preparations are not standardized and exhibit wide variability in platelet and white blood cell concentrations and the use of thrombin activators. How variations in PRP composition may impact clinical outcomes is also unclear. 4 Mishra et al 5 proposed classifying these types in 3 categories: the presence of white blood cells (e.g., leukocyte-rich or -poor), whether the PRP is activated or not, and the concentration of platelets.

Several factors have contributed to the growing popularity of biologic therapies despite the dearth of high-quality clinical trials supporting their use. Musculoskeletal conditions are both severe and prevalent. Conventional treatment, for the most part, is lacking in success. Platelet-rich plasma has the appeal of a simple, minimally invasive treatment with little regulation, which can be easily administered via local injection by clinicians. In addition, the biotechnology companies that manufacture the equipment used to assist in producing these therapies have conducted nationwide marketing directly to clinicians and consumers, touting success with high profile professional athletes.

A collection and preparation system is used to collect a small sample of blood at the patient’s point of care or clinical laboratory. The systems used for preparing autologous platelet-derived growth factors are United States (U.S.) Food and Drug Administration (FDA) approved under the 510(k) process. 6 https://web.archive.org/web/20221128045708/https://www.fda.gov//vaccines-blood-biologics/substantially-equivalent-510k-device-information/cleared-510k-submissions-supporting-documents-2021. While the technology to obtain PRP is FDA-approved, PRP itself is currently not indicated for direct injection. Centrifugation of this blood sample separates the denser red cells from the plasma. The plasma components are divided into a buffy coat and an adjacent layer. The buffy coat contains leucocytes and most of the platelets. The adjacent layer of plasma is less rich in platelets and has few leucocytes. 7

The contractor cites 82 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2021-12-12
Current revision effective
2021-12-12
MCD version
16

The contractor lists one National Coverage Determination as related: NCD 270.3 Blood-Derived Products for Chronic Non-Healing Wounds. Where an NCD speaks, it controls; the LCD can only address what the NCD leaves open.

Other related documents: A58924 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the First Coast Service Options, Inc. hub lists every other active policy from the same contractor.

The same policy title at other contractors

Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L39071 cover?

Platelet rich plasma injections and/or applications are considered not medically reasonable and necessary for any use outside of the National Coverage Determination (NCD) 270.3 Blood-Derived Products for Chronic Non-Healing Wounds. The full 52-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L39071 apply to?

First Coast Service Options, Inc. applies it to Medicare claims in 1 state plus 2 territories: FL, PR, VI. It binds only that contractor; 3 other contractor versions of this title govern other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L39071?

The current export links no billing and coding article with a diagnosis list to LCD L39071, so First Coast Service Options, Inc. decides coverage on the 52-word policy text and the documentation in the record rather than by an automated diagnosis edit.

How do I appeal a denial under LCD L39071?

A denial under LCD L39071 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications, then file a redetermination with First Coast Service Options, Inc. within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.